Seminar

22 November 2017: Seminar on Biosimilars & Competition Law

22 November 2017: Seminar on Biosimilars & Competition Law

16.10.2017 EU law

On Wednesday 22 November 2017, Stibbe will organise a seminar on Biosimilars & Competition Law in Brussels. This seminar will be co-organized by competition lawyers from Stibbe and competition economists from CRA so as to cover both legal and economic angles relevant to this increasingly important field. 

Given the ever increasing economic significance of biologics in the pharmaceutical space – as well as signals from regulators that this field will come into focus shortly – it  is time to explore the implications of the competition rules for business behavior in this area. This includes a discussion of the following topics/questions: 

  • What can we expect from competition authorities in this space?
  • To what extent do the competition law principles developed for synthetic drugs apply to the biological space?
  • How does this play out in the context of life cycle management?  
  • What stance do authorities take in merger control cases involving biologics?
  • What about pricing strategies? Is there more reason for concern following cases like Aspen (EU) and Pfizer (UK)?

Our intention is to go beyond scratching the surface on these topics in order to provide guidance for pharmaceutical companies in an area which we feel is receiving insufficient attention in the competition law domain. 

For more information and to register, please send an email to: StibbeEvents@Stibbe.com.

A provisional program can be found below: 

  • 12:00 - 12:30: Registration
  • 12:30 - 12:45:  Introduction by chair - Stibbe/CRA
  • 12:45 - 13:15: Keynote speech by Paul Paul Csiszár, Director of "Basic Industries, Manufacturing and Agriculture", responsible for the Commission’s pharma unit
  • 13:15 - 13:45: Industry trends in biosimilars - Tim Wilsdon, CRA  
  • 13:45 - 14:30: Biologics in EU merger control: current status and likely issues in the future - Stibbe
  • 14:30 - 15:00: Break
  • 15:00 - 15:45: Competition law boundaries of life cycle management strategies: application to the biologics space - Stibbe
  • 15:45 - 16:30: Pricing practices & antitrust: law and economics - Raphaël De Coninck, CRA
  • 16:30 - 16: 45: Closing
  • 16:45 - 17:30: Drink

When: 22 November 2017 from 12.00 -17.30.

Where: Stibbe office: Central Plaza - Loksumstraat 25 Rue de Loxum - 1000 Brussels

stibbe_logo_background_01    logo - CRA

 

Team

Related news

23.11.2017 EU law
The precautionary principle: outdated protection against authorized GMOs?

Articles - Member States must not - on the sole basis of the precautionary principle - adopt national emergency measures prohibiting certain authorised genetically modified organisms (GMOs). This was decided by the EU Court of Justice in the recent Fidenato case. While such a decision ensures a harmonized approach to GMO regulation, it undermines the possibility for Member States to prohibit the cultivation of already-authorized genetically modified crops for which there is no new scientific evidence.

Read more

01.11.2017 EU law
Nike can restrict sales via online platforms within its selective distribution system

Short Reads - On 4 October 2017, the District Court of Amsterdam ruled* in favour of sports goods manufacturer Nike in an action against a distributor, Action Sport, which had not complied with Nike's selective distribution policy. The District Court found that Nike's selective distribution system, which included a ban on sales via non-authorised online platforms, was compatible with competition law as it sought to preserve the luxury image of Nike's products.

Read more

01.11.2017 EU law
General Court upholds fine for 'gun jumping' EU merger control procedure

Short Reads - On 26 October 2017, the General Court (GC) dismissed an appeal lodged by Harvest Marine, a Norwegian seafood company, against a EUR 20 million fine imposed by the European Commission. The fine was imposed on Harvest Marine in 2014 for implementing its acquisition of Norwegian salmon producer Morpol before obtaining the required clearance from the Commission under the EU merger control rules, also referred to as "gun jumping" [see our August 2014 Newsletter].

Read more

Our website uses cookies: third party analytics cookies to best adapt our website to your needs & cookies to enable social media functionalities. For more information on the use of cookies, please check our Privacy and Cookie Policy. Please note that you can change your cookie opt-ins at any time via your browser settings.

Privacy and Cookie Policy